HC Wainwright Forecasts Ardelyx’s Q1 Earnings (NASDAQ:ARDX)

Ardelyx, Inc. (NASDAQ:ARDX) – HC Wainwright cut their Q1 2025 earnings per share estimates for shares of Ardelyx in a report issued on Monday, November 11th. HC Wainwright analyst E. Arce now forecasts that the biopharmaceutical company will post earnings of ($0.15) per share for the quarter, down from their previous forecast of ($0.05). HC Wainwright has a “Neutral” rating and a $5.50 price target on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Ardelyx’s Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.47) EPS, FY2026 earnings at $0.03 EPS, FY2027 earnings at $0.63 EPS and FY2028 earnings at $1.06 EPS.

Several other equities research analysts also recently weighed in on ARDX. Citigroup decreased their price target on Ardelyx from $12.00 to $10.00 and set a “buy” rating for the company in a report on Monday, November 4th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Ardelyx in a report on Friday, August 2nd. Finally, StockNews.com upgraded shares of Ardelyx from a “sell” rating to a “hold” rating in a research note on Wednesday, July 31st. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $10.42.

Ardelyx Trading Up 4.7 %

Shares of ARDX stock opened at $4.71 on Wednesday. The company has a market capitalization of $1.12 billion, a P/E ratio of -15.70 and a beta of 0.92. The company has a current ratio of 4.03, a quick ratio of 3.87 and a debt-to-equity ratio of 0.64. The business’s 50 day moving average is $5.97 and its two-hundred day moving average is $6.27. Ardelyx has a twelve month low of $3.83 and a twelve month high of $10.13.

Insider Activity at Ardelyx

In other Ardelyx news, insider David P. Rosenbaum sold 20,507 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $6.00, for a total value of $123,042.00. Following the sale, the insider now owns 158,502 shares of the company’s stock, valued at $951,012. This represents a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Justin A. Renz sold 5,289 shares of Ardelyx stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $5.86, for a total value of $30,993.54. Following the transaction, the chief financial officer now owns 295,257 shares of the company’s stock, valued at $1,730,206.02. This represents a 1.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 247,983 shares of company stock worth $1,514,002 over the last 90 days. Company insiders own 5.90% of the company’s stock.

Institutional Trading of Ardelyx

Institutional investors and hedge funds have recently made changes to their positions in the stock. Nisa Investment Advisors LLC boosted its stake in shares of Ardelyx by 1,026.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,548 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 3,233 shares during the last quarter. Redwood Wealth Management Group LLC purchased a new stake in shares of Ardelyx in the second quarter valued at $62,000. Coastal Bridge Advisors LLC purchased a new stake in Ardelyx in the 2nd quarter valued at about $74,000. Helen Stephens Group LLC acquired a new position in shares of Ardelyx during the 3rd quarter valued at about $76,000. Finally, Paloma Partners Management Co acquired a new stake in shares of Ardelyx in the first quarter worth approximately $86,000. 58.92% of the stock is currently owned by hedge funds and other institutional investors.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.